HDAC-IN-42

Cat. No.:	HY-147892
CAS No.:	2454024-18-9
Molecular Formula:	$C_{20}H_{15}NO_7$
Molecular Weight:	381.34
Target:	HDAC; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HDAC-IN-42 (compound 14f) is a potent and selective HDAC inhibitor with IC_{50} values of 0.19 and 4.98 μM for HDAC1 and HDAC6, respectively. HDAC-IN-42 shows anticancer and anti-proliferative activity. HDAC-IN-42 induces apoptosis and cell cycle arrest at G2/M phase[1].	
IC_{50} & Target	HDAC1 0.19 μM (IC_{50})	HDAC6 4.98 μM (IC_{50})
In Vitro	HDAC-IN-42 (compound 14f) shows anti-proliferative activity with C_{50}s of 9.56, 13.32, 10.46, 6.91 μM for MCF-7, HCT-116, HepG2, Hela cells, respectively[1]. HDAC-IN-42 (1, 5, 10 μM; 24 h) reduces the colony formation and increases the expression of histone H3 and α-tubulin in HeLa cells[1]. HDAC-IN-42 (1, 5, 10 μM; 48 h) induces apoptosis and cell cycle arrest at G2/M phase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Ding J, et al. Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities. Bioorg Chem. 2020 Aug;101:104023.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA